Teva Reports Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Teva Pharma (TEVA) PT Lowered to $9 at Cowen
August 7, 2019 11:14 AM EDTCowen analyst Ken Cacciatore lowered the price target on Teva Pharma (NYSE: TEVA) to $9.00 (from $16.00) while maintaining a Market Perform rating.
The analyst commented, "Teva continues to perform as well as can be expected, with good cost reductions while still investing in Austedo & Ajovy.... More
Teva Pharma (TEVA) Tops Q2 EPS by 3c, Reaffirms Guidance
August 7, 2019 7:01 AM EDTTeva Pharma (NYSE: TEVA) reported Q2 EPS of $0.60, $0.03 better than the analyst estimate of $0.57. Revenue for the quarter came in at $4.3 billion versus the consensus estimate of $4.25 billion.
Full year 2019 revenues and EPS guidance reaffirmedFor earnings history and earnings-related data on Teva Pharma (TEVA) click here.
... More